The Efficacy of the BCG Vaccine against Newly Emerging Clinical Strains of Mycobacterium tuberculosis

Abstract excerpt

To date, most new vaccines against Mycobacterium tuberculosis, including new recombinant versions of the current BCG vaccine, have usually been screened against the laboratory strains H37Rv or Erdman. In this study we took advantage of our recent work in characterizing an increasingly large panel of newly emerging clinical isolates [from the United States or from the Western Cape region of South Africa], to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Immune responses and vaccinations
• Share to Mycobacterium research and diagnosis
• Share to Tuberculosis Research and Epidemiology